CROWN BIOSCIENCE KICKS OFF SINGAPORE LABORATORY, INITIATES LOCAL COMMERCIAL PARTNER

KUALA LUMPUR, March 10 (Bernama) -- Crown Bioscience has opened a new site in Singapore to expand its capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.

The new facility will initially offer a broad portfolio of high-demand cell line-derived xenograft (CDX) and syngeneic models, alongside supporting analytical biomarker capabilities including flow cytometry and pathology services.

Commenting on the opening of the new laboratory, executive director and general manager of the Singapore facility, Keefe Chng, PhD said: “We are extremely excited to join the local biomedical community.

“Our core capabilities and experience will help the booming local biotech industry advance their preclinical and translational studies, while at the same time enable Crown Bioscience to bring unique high-end technologies to our global partners.”

According to a statement, the company is also collaborating with the established biomedical community in Singapore to bring not only the foundational capabilities of Crown Bioscience’s preclinical services to Singapore but also novel technologies and services.

To support the growth goals for the Singapore site, and with a particular focus on the burgeoning local biotech industry, Crown Bioscience has entered into a distribution agreement with Biosys Corporation Pte Ltd, a specialised commercial partner with unique contacts within the Singaporean life sciences ecosystem.

The investment in Singapore reflects a broader strategy to increase Crown Bioscience’s ability to support APAC-based clients with a local presence.

In 2022, the company announced a joint venture launch with sister company MBL in Japan, alongside facility expansions and upgrades to its Chinese presence.

Founded in 2006, Crown Bioscience, a global contract research organisation and JSR Life Sciences company, has 12 facilities across the United States, Europe, and Asia.

-- BERNAMA